Results 111 to 117 of about 180 (117)

Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study

Multiple Sclerosis Journal, 2019
Gavin Giovannoni, Per Soelberg Sorensen, Giancarlo Comi   +2 more
exaly  

Treatment with cladribine tablets: real-world insights

Medicom Conference Report ACTRIMS 2025
openaire   +1 more source

Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England

Journal of Medical Economics, 2018
Gérard Harty, Robert Hettle, Schiffon L Wong   +2 more
exaly  

Cladribine tablets cost effective in relapsing-remitting MS

PharmacoEconomics & Outcomes News, 2019
openaire   +1 more source

Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study

Frontiers in Immunology
Lidia Gardner, Hulin Jin, Chan Andrew
exaly  

Real world experience with cladribine tablets for multiple sclerosis at four academic multiple sclerosis centers

Multiple Sclerosis and Related Disorders
Devon Conway, Nicolas Thompson, Robert Naismith   +2 more
exaly  

Update on safety profile of cladribine tablets yields positive results

Medicom Conference Report ACTRIMS 2025
openaire   +1 more source